- Home
- MRNA vs ICLR Comparison
MRNA vs ICLR Comparison
Compare MRNA & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- ICLR
- Stock Information
- Founded
- MRNA 2010
- ICLR 1990
- Country
- MRNA United States
- ICLR Ireland
- Employees
- MRNA N/A
- ICLR N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- MRNA Health Care
- ICLR Health Care
- Exchange
- MRNA Nasdaq
- ICLR Nasdaq
- Market Cap
- MRNA 13.4B
- ICLR 11.6B
- IPO Year
- MRNA 2018
- ICLR 1998
- Fundamental
- Price
- MRNA $34.15
- ICLR $187.01
- Analyst Decision
- MRNA Hold
- ICLR Buy
- Analyst Count
- MRNA 20
- ICLR 13
- Target Price
- MRNA $46.76
- ICLR $211.92
- AVG Volume (30 Days)
- MRNA 9.4M
- ICLR 1.6M
- Earning Date
- MRNA 08-01-2025
- ICLR 07-23-2025
- Dividend Yield
- MRNA N/A
- ICLR N/A
- EPS Growth
- MRNA N/A
- ICLR 13.11
- EPS
- MRNA N/A
- ICLR 9.73
- Revenue
- MRNA $3,177,000,000.00
- ICLR $8,089,820,000.00
- Revenue This Year
- MRNA N/A
- ICLR N/A
- Revenue Next Year
- MRNA $9.70
- ICLR $1.69
- P/E Ratio
- MRNA N/A
- ICLR $19.21
- Revenue Growth
- MRNA N/A
- ICLR N/A
- 52 Week Low
- MRNA $23.15
- ICLR $125.10
- 52 Week High
- MRNA $125.68
- ICLR $338.67
- Technical
- Relative Strength Index (RSI)
- MRNA 64.57
- ICLR 71.84
- Support Level
- MRNA $30.88
- ICLR $139.15
- Resistance Level
- MRNA $35.59
- ICLR $211.00
- Average True Range (ATR)
- MRNA 1.48
- ICLR 7.52
- MACD
- MRNA 0.11
- ICLR 4.29
- Stochastic Oscillator
- MRNA 74.05
- ICLR 66.61
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.